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DHE   dihydroethidium 
GSK3β  glycogen synthase-3 beta 
IL-6 interleukin-6 
mtDNA mitochondrial DNA 
MCP-1 monocyte chemoattractant protein-1 
NAD   nicotinamide adenine dinucleotide 
NADH   nicotinamide adenine dinucleotide (reduced form) 
NO nitric oxide 
eNOS endothelial nitric oxide synthase 
NOX4 NADPH oxidase 4 
O.C.T   optimal cutting temperature compound 
qRT-PCR real-time quantitative reverse transcription polymerase chain 
reaction 
SDS   sodium dodecyl sulfate 
TMRM tetramethylrhodamine 
XO Xanthine oxidase 








Uric acid is a purine degradation product but also an important antioxidant and ROS 
scavenger. Experimental settings that mimic myocardial ischemia-reperfusion have not 
included uric acid despite that it is always present in human extracellular fluid and 
plasma. We hypothesized that uric acid has an important role in myocardial ROS 
scavenging. Here, we tested the cardiac response to uric acid on infarct size following 
ischemia-reperfusion with and without exacerbated oxidative stress due to acute pressure 
overload and during preconditioning.  We also examined mitochondrial respiration and 
ROS-induced mitochondrial permeability transition pore opening. Under exacerbated 
ROS stress induced by high pressure perfusion, uric acid lowered oxidative stress and 
reduced infarct size. In contrast, uric acid blocked cardioprotection induced by ischemic 
preconditioning. However, this effect was reversed by probenecid, an inhibitor of cellular 
uptake of uric acid.  In accordance, in intact cardiomyocytes, extracellular uric acid 
reduced the susceptibility of mitochondria towards opening of the permeability transition 
pore, suggesting that uric acid may prevent ischemia-reperfusion injury due to 
scavenging of maladaptive ROS. Moreover, as uric acid also scavenges also adaptive 
ROS, this may interfere with preconditioning. Altogether, uric acid might be a 







In humans and other higher primates, uric acid (UA) is the end-product of purine 
metabolism whereas in other mammals the presence of uricase ensures its further 
degradation (Sautin and Johnson 2008). As such, UA is at markedly lower levels in 
rodent models of ischemic heart disease. UA is synthesized by xanthine oxidase (XO) 
that can in turn be induced by myocardial ischemia. In line with this, the extracellular 
release of purine metabolites characterizes oxygen shortage and ischemic cell damage 
(Farthing et al. 2015).  Chronically, elevated serum UA is associated with increased risk 
of heart failure, including heart failure with preserved ejection fraction (HFpEF) (Liese et 
al. 1999; Norvik et al. 2017; Norvik et al. 2016; Odden et al. 2014). In addition, elevated 
serum UA levels may predict the risk for myocardial infarction and underlie adverse 
outcomes in patients with myocardial infarction undergoing percutaneous coronary 
intervention (Mandurino-Mirizzi et al. 2018). Reactive oxygen species (ROS) are a 
byproduct when XO catalyzes the reactions of hypoxanthine to xanthine and xanthine to 
uric acid. A number of experimental studies have elucidated a detrimental role for XO-
derived ROS produced by XO in cardiac ischemia (Akizuki et al. 1985; Chambers et al. 
1985; Granger and Kvietys 2015; Mozaffari et al. 2011; Mozaffari et al. 2013) and in the 
pathology of heart failure (Jia et al. 2015; Norvik et al. 2016). In addition, previous 
studies have shown that high levels of UA also exacerbate oxidative stress and an 
inflammatory response (Gersch et al. 2009; Kanbay et al. 2013; Sautin et al. 2007).  
  UA functions as an antioxidant in human plasma, and is a potent scavenger of 
peroxynitrite in the extracellular compartment (Juhasz et al. 2011; Kuzkaya et al. 2005). 
Studies of UA as acute treatment have indicated this action may improve cardiac 
dysfunction following ischemia-reperfusion (Lee et al. 2003) however, exogenous 
administration of UA may also block cardioprotection induced by conditioning (Babiker 
et al. 2017). These differences may be dependent on intracellular uptake of UA. Despite 
the role for UA in scavenging ROS and although it is always present in human plasma, 
experimental settings to mimic myocardial ischemia-reperfusion (IR) have not, to our 
knowledge, included UA. This warranted further investigation of the actions of UA in IR. 
Thus, in the present study our aim was to investigate effects of the presence of UA, at a 
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concentration comparable to what is normally found in human plasma during 
cardiovascular ischemic stress, in an ex-vivo model of myocardial IR. We hypothesized 
that UA had an important role in myocardial ROS scavenging and may also alter ROS-
induced stress adaptation central to ischemic preconditioning (IPC). Thus, we tested the 
cardiac response to UA on infarct size following IR during exacerbated oxidative stress 
due to acute pressure overload, during preconditioning and in mitochondrial ROS stress. 
Under these conditions, we demonstrate that in the presence of UA, ischemia-reperfusion 
injury was reduced, as well as oxidative stress. However, cardioprotection induced by 





Rats were treated in accordance with the Guide for the Care and Use of Laboratory 
Animals (8th edition, National Academies Press) and the guidelines on accommodation 
and care of animals formulated by the European Convention for the Protection of 
Vertebrate Animals for Experimental and Other Scientific purposes. All animal 
experiments in the present study were approved by the Norwegian National Animal 
Research Authority (FDU ID 2929), as well as the local authority (Department of 
Comparative Medicine, UiT-Arctic University of Norway) of the National Animal 
Research Authority in Norway .  
 
Male Wistar rats (Charles River, Germany) were given ad libitum access to standard 
chow and water and housed in a room with 12-h:12-h light-dark cycle at 21° C. On the 
day of experiments, they were heparinized (200 IU i.p) and anesthetized (pentobarbitone 
sodium 50 mg/kg i.p). The heart was excised and prepared for either perfusion, or cell or 
mitochondrial isolation.   
 
Isolated heart perfusions. All hearts were Langendorff-perfused using Krebs-Henseleit 
bicarbonate buffer (KHB) containing 2.1 mM Ca++ and 11 mM glucose, equilibrated with 
95% O2 - 5% CO2 at 37° C. Standard perfusion pressure was set to 100 cm H2O (73.6 mm 
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Hg). For experiments investigating low versus high perfusion pressure, perfusion 
pressure was set at 80 (LP) and 200 cm H2O (HP) (58.8 and 147 mm Hg), respectively. A 
water-filled latex balloon, connected to a pressure transducer, was inserted into the left 
ventricle via the left atrium, and inflated to set a left ventricular end-diastolic pressure 
(LVDevP) between 0-10 mmHg as baseline, which was thereafter left unchanged.  
 
Experimental protocols in isolated hearts. All hearts underwent 20 minutes stabilization 
followed by either 25 minutes regional ischemia (coronary artery ligation) or 30 minutes 
of global ischemia and 120 minutes of reperfusion (Figure 1). Ischemic preconditioning 
(IPC) was induced by one cycle of 5 minutes global ischemia followed by 5 minutes of 
reperfusion, prior to the ischemia and reperfusion protocol (I/R). In one set of 
experiments, uric acid (100 or 500 µM) was administered in the perfusion buffer for a 
total of 10 minutes prior to IPC and regional I/R. To test whether cellular uric acid uptake 
altered the infarct-sparing effect of IPC, we added probenecid (1 µM), an inhibitor of 
organic anion transporter and pannexin channel (Silverman et al. 2008), to the perfusion 
buffer. Probenecid was added to the buffer 5 minutes prior to the introduction of uric acid 
and followed by global I/R. In another set of experiments, isolated perfused hearts were 
subjected to regional ischemia and reperfusion during LP or HP-perfusion. Uric acid (500 
µM) or allopurinol (1 mM) was added to the perfusion buffer for assessment of infarct 
size and functional recovery under LP or HP-perfusion.  
 
Infarct size determination. For regional infarct studies, a silk suture was placed around 
the main branch of the left coronary artery and ischemia was induced by tightening the 
suture using a snare. Following reperfusion the coronary artery was again ligated and 
Evans Blue dye was infused via the aorta to demarcate the myocardial risk zone. For 
infarct size measurements, the hearts were weighed, frozen at -20°, and cut into 2 mm 
thick slices. The slices were incubated for 15 minutes in 1% triphenyl-tetrazolium 
chloride (TTC; Sigma-Aldrich) in phosphate buffer (pH 7.4, 37° C), immersed in 10% 
formaldehyde to enhance the contrast between viable and necrotic tissue, and thereafter 
the tissue slices were scanned to obtain a digital image. Infarct size was expressed as the 
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ratio of infarcted area (lacking staining with TTC) to risk zones or to the ventricle area 
when using global ischemia using ImageJ software (NIH). 
 
Western blot of heart tissue. To investigate whether perfusion pressure altered pre-
ischemic activation of kinase cascades related to cell survival, left ventricle tissue was 
rapidly frozen in liquid nitrogen and tested for phosphorylation of Akt, p44/42 MAPK, 
GSK3β.  Heart tissue was homogenized in 10 ml ice-cold PBS buffer containing 1% 
Igepal CA-630, 0.1 % SDS, 0.5% Sodium Deoxycholate, 5mM EDTA, 2mM EGTA, 100 
ul Phosphatase inhibitor 2, 100 ul Phosphatase inhibitor 3, 10 ul beta-Mercaptoethanol, 1 
tablet EDTA-free Complete Protease inhibitor cocktail (all supplied by Sigma). 
Thereafter the homogenate was centrifuged at 14000 g for 10 min at 4°C and protein 
content was measured (Bradford, BioRad protein assay). Supernatant samples (30 µg 
protein) underwent SDS-page electrophoresis using a standard Laemmli loading buffer 
(Criterion anyKD, Biora). The following antibodies from Cell Signaling Technology 
were used: phospho-GSK-3β (Ser9) #9336, GSK-3β (3D10) #9832, phospho-Akt 
(Ser473) #9271, Akt #9272, p44/42 MAPK (ERK1/2) #9102, phospho p44/42 MAPK 




Detection of intracellular ROS production in heart tissue by dihydroethidium (DHE) 
staining. DHE reacts with superoxide radicals to form ethidium bromide, which in turn 
intercalates with DNA to provide fluorescence as a marker of ROS, especially superoxide 
radical generation (Camara et al. 2004; Kevin et al. 2003). DHE was used to investigate if 
ROS production at reperfusion in HP-perfused hearts was influenced by allopurinol or 
uric acid treatment. DHE (10 mM) was added to the perfusion-buffer for 3 minutes prior 
to global ischemia and during the first 5 minutes of reperfusion such that the ROS 
indicator was present at the same time as allopurinol or uric acid. Following experiments, 
left ventricular tissue was embedded in O.C.T compound, frozen in cooled isopentane 
and stored at -70oC. The samples were cryo-sectioned and imaged under an 
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epifluorescence microscope. Between 18-20 images from each heart was obtained for 
quantification using Image J software. 
 
 
Mitochondrial permeability transition (mPTP) in cardiomyocytes. To examine if the 
extracellular concentration of uric acid affected the susceptibility of mitochondria in 
intact cardiomyocytes towards opening of the permeability transition pore when exposed 
to ROS, we incubated tetra methyl rhodamine methyl ester (TMRM) loaded 
cardiomyocytes with different concentrations of uric acid.  Hypoxanthine, the precursor 
of XO derived uric acid, was used as control. Cardiomyocytes were isolated using 
collagenase (Worthington type 2, Lakewood, NJ 08701, US) based on the method 
described by Myrmel et al. 1991 (Myrmel et al. 1991). Freshly isolated cells were 
resuspended in HEPES buffer containing TMRM (Molecular Probes) 125 nM for 60 min 
at room temperature. Isolated TMRM loaded cardiomyocytes were then placed in an 
open glass bottomed chamber, allowed time to settle and superfused with TMRM 
containing HEPES with and without the addition of uric acid (0, 10, 50, 100 500 µM) or 
hypoxanthine (0, 10, 50, 100, 500 µM). Laser confocal microscopy (Zeiss 510 LSM, 
excitation at 543 nm and emission above 560) was used in line scan mode, and focused 
on a row of mitochondria to obtain a timed series of loss of TMRM from selected 
mitochondrial compartments (Juhaszova et al. 2004). By this technique, the effect of uric 
acid on ROS dependent mPTP transition was quantified as time to mPTP transition.    
 
 
Mitochondrial respiration. To investigate if uric acid present in myocardial cells or taken 
up from the cell-surroundings influenced mitochondrial respiration, mitochondria were 
isolated from rat hearts and respiration examined in 6 paired experiments with and 
without uric acid (500 uM) present. Isolation of mitochondria was performed using the 
procedure described by Palmer et al. (Palmer et al. 1977) with slight modifications. 
Briefly, heart tissue was weighed and placed in a buffer containing (in mM): 100 KCl; 50 
MOPS; 1 EGTA; 5 MgSO4; 1 ATP and pH 7.4. The tissue was minced with scissors, and 
homogenized with a Polytron for 7 seconds followed by 10 min incubation with 5 mg/mL 
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trypsin at 4 ºC. Buffer with 2 mg/ml BSA was then added to the tissue supernatant and 
homogenized with two strokes of a Potter-Elvehjem homogenizer (Glas-Col, Terre 
Haute, IN, USA) and centrifuged at 590 g for 10 min at 4º C. The supernatant was 
filtered through a nylon net (NITEX 300 lm; Yulee, FL, USA) and centrifuged at 3000 g 
for 10 min at 4oC. The mitochondrial pellet was resuspended in buffer (4º C) and 
centrifuged again at 3000 g for 10 min. The new pellet was now resuspended in buffer 
containing (in mM):100 KCl, 0.5 EGTA, 50 MOPS, pH 7.4, and centrifuged at 3000 g 
for 10 min at 4oC. The final pellets were resuspended and left on ice for 30 min to 
stabilize the membranes. Measurement of mitochondrial oxygen consumption was 
performed in duplicate by Oxygraph-2k (Oroboros, Austria) using a respiration medium 
containing in mM:100 KCl; 50 MOPS; 1 EGTA; 5 KH2PO4 and BSA 1 mg/mL, pH = 7.4 
in a closed 2 mL chamber at 37ºC. Uric acid 500 µM was added to one of the two parallel 
chambers of the oxygraph at the start of each experiment. Glutamate (10 mM) and malate 
(1 mM) were used to assess complex I driven respiration. After obtaining a stable state 2 
respiration, ADP was added to a final concentration of 200µM (state 3). Thereafter 
oxygen consumption was recorded after the depletion of ADP (state 4) and ADP added to 
final concentration 2 mM to obtain maximal ADP-stimulated respiration. Finally, leak 
supported respiration was assessed by adding oligomycin (4 µg/mL) to inhibit the ATP-
synthase. All values were normalized to citrate synthase activity measured 
spectrophotometrically using the enzymatic conversion of 5,5′-dithiobis (2-nitrobenzoic 
acid) to thionitrobenzoic acid which has an intense absorption at 412 nM (Holloszy et al. 
1970; Kuznetsov et al. 2002). 
 
Statistics. All results are presented as mean ± SEM. Statistical comparisons were 
performed with SigmaPlot version 14.0 (Systat software) using one-way ANOVA with 
the Holm-Sidak post-hoc test or Student’s t-test where appropriate, where differences of 
p < 0.05 were considered significant. For the one-way ANOVA analysis, the F-value and 
p-value are also presented in the figure text.  
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Figure 1. Ischemia-reperfusion (IR) protocols in isolated rat hearts with exacerbated ROS stress 
or ischemic preconditioning (IPC). To induce oxidative stress, hearts were perfused with high 
pressure (HP) or low pressure (LP), and underwent regional ischemia (RI) followed by 
reperfusion and measurement of infarct size. IPC was induced by 1 cycle of 5 minutes global 





Uric acid and allopurinol protected high-pressure perfused hearts against ischemia 
reperfusion injury.   
 
In agreement with other studies (Mozaffari et al. 2011; Mozaffari and Schaffer 2008), 
pressure overload resulted in significantly higher % infarct/risk zone (53.5±2.2 versus 
30.6±4.0% for HP vs. LP, respectively) (Fig.2A) and caused oxidative stress (Figure 5). 
To assess ROS-scavenging effects during HP-perfusion we used 500 µM concentration of 
UA, as 100 µM did not inhibit cardioprotection by IPC (Figure 3A). UA reduced infarct 
size in HP- perfused isolated hearts to 41.1±3.9 %. The presence of 1 mM allopurinol in 
the buffer also reduced infarct size in pressure-overloaded hearts to 37.0±4.7. None of the 
treatments reduced infarct size in LP-perfused hearts (data not shown).  
Pressure overload resulted in increased cardiac work as shown by increased LV 
developed pressure (LVDevP) and dp/dt max as compared to LP-perfused hearts (Figure 
2B). Neither uric acid nor allopurinol altered developed pressure. Perfusion with 
allopurinol in pressure overloaded hearts resulted in an increased dP/dt max both at 
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baseline and at the end of the ischemia-reperfusion protocol above HP alone (5397.7±333 
vs. 7180.2±768.7 and 2551.9±146.2 vs. 3541-7±488.0, for HP-perfused hearts with and 
without allopurinol, respectively), which was not observed with UA. 
Figure 2. A) Both uric acid (UA) and allopurinol prevented high-pressure perfusion induced 
increase in infarct size following regional ischemia reperfusion. Mean ± SEM, n=5-9 for all 
groups. (F=2.798, p<0.045) and p<0.05 vs. low pressure (LP) - perfusion. B) High-pressure (HP) 
perfusion increased baseline cardiac contractile function and coronary flow. Only allopurinol 
maintained increased coronary flow following ischemia-reperfusion. Left ventricle developed 
pressure (LVDevP) was lower during reperfusion in hearts treated with uric acid (UA) and 
remained similar within the other groups.  Mean ± SEM, n=5-10. Coronary flow: At baseline 
(F=37.103, p<0.001), *p<0.05 vs. low-pressure (LP), and #p<0.05 vs. HP; and at time 120 
minutes (F=6.77, p<0.002), *p<0.05 vs. LP and and #p<0.05 vs. HP.  LVDevP: At baseline 
(F=6.77, p< 0.002), *p<0.05 vs. LP; and at time 120 min (F=3.67, p<0.026), #p<0.05 vs. HP. 
Dp/dtmax: (F=11.04, p< 0.001),*p<0.05 vs. LP and (F=11.041, p < 0.001), #p<0.05 vs. HP.  No 
significant differences in dp/dtmin at baseline or during reperfusion.  
 
 
Uric acid blocked cardioprotection by ischemic preconditioning (IPC) 
 
The addition of either 100 or 1000 µM UA alone did not alter the % infarct/risk zone 
(data not shown).  However, UA inhibits ischemic preconditioning (IPC) -induced 
cardioprotection in isolated rat hearts subjected to IPC under standard perfusion pressure 
prior to ischemia reperfusion. At low concentrations (100 µM) UA did not prevent IPC-
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induced reduction in infarct size. At elevated levels (500 µM), there was no effect of IPC 
on infarct size (Figure 3A) suggesting that UA may scavenge ROS and prevent ROS 
signalling which is essential in IPC cardioprotection. The infarct lowering effect of IPC 
was observed in the presence of allopurinol, which is known to inhibit ROS production 
by xanthine oxidase. In another set of experiments, probenecid was added to the 
perfusion buffer to limit cellular uptake of UA (Figure 3B). Probenecid did not alter 
infarct size on its own; however, it did maintain the infarct sparing effects of IPC in the 
presence of UA. This suggests that probenecid diminished the intracellular scavenging 
ability of UA and did not disturb the ROS-related signalling central in IPC-induced 
protection.  
 
Figure 3. A) Uric acid (UA) but not allopurinol inhibits ischemic preconditioning (IPC) -induced 
cardioprotection in isolated rat hearts subjected to IPC prior to regional ischemia reperfusion. 
Mean ± SEM, n=5-8. (F=18.9, p< 0.001), *p<0.05 vs. control (without IPC). B) Blocking cellular 
uric acid (UA) uptake by probenecid maintains ischemic preconditioning (IPC) -induced 
cardioprotection in isolated rat hearts subjected to IPC prior to global ischemia reperfusion. Mean 
± SEM, n=5-8 for all groups. (F=8.36, p<0.001), *p<0.05 vs. control (no IPC). 
 
Uric acid and allopurinol reduced ROS content but did not alter survival protein 
kinases 
 
Under normoxic conditions, HP-perfusion elevated phosphorylation of protein kinases 
GSK-3β, ERK and AKT as compared to hearts that underwent LP perfusion (Figure 4). 
Neither UA nor allopurinol blocked this increase.  
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DHE-reactive ROS in tissue samples harvested at reperfusion following 25 min global 
ischemia was higher in HP-perfused hearts compared to LP. Both Allopurinol and UA 
blocked the HP-perfusion related ROS increase (Figure 5). 
 
 Figure 4. High pressure (HP) perfusion induced phosphorylation of cell survival kinases as 
compared to low pressure (LP) and was not altered by treatment with uric acid (UA) or 
allopurinol. The relative balance between phosphorylated and total GSK3β, PKB/AKT and ERK, 
and their representative western blots, in hearts harvested prior to ischemia in groups LP, HP, HP 
+ Allo, LP + UA. Mean ± SEM, n=5-6. GSK: (F=2.746, p=0.07), *p<0.05 vs. LP; ERK: 




Figure 5. High pressure (HP) perfusion increased ROS content measured by dihydroethidium 
(DHE) fluorescence intensity but this was reduced in the presence of uric acid (UA) and 
allopurinol. Mean ± SEM, n=5 for all groups. (F=7.77, p<0.002), *p<0.05 vs low pressure (LP) 




Uric acid protected mitochondria in isolated cardiomyocytes against permeability 
transition but reduced OXPHOS in isolated heart mitochondria 
 
Addition of UA (500 µM) to the superfusion chamber of isolated cardiomyocytes 
protected mitochondria as seen by the significantly increased time to mitochondrial 
permeability transition pore opening (mPTP) (Figure 6A). Increased time to pore opening 
was evident also at lower and higher concentrations of UA. However, comparable 
experiments with the UA precursor, purine hypoxanthine, did not reveal significant 
protection against pore opening.  
In isolated mitochondria, the addition of UA (500 µM) resulted in a slight reduction in 
respiratory control ratio (RCR; state 3/state 4) which may suggest reduced mitochondrial 
function (Figure 6B). Complex I driven respiration (state 3) at low and saturating levels 
of ADP was significantly reduced compared to that observed in controls (12.6% and 
15.2%, respectively). Oligomycin-induced leak respiration (State 4) was unchanged 
suggesting that UA did not increase mitochondrial uncoupling (Brand and Nicholls 
2011). 
 
Figure 6. A) Time to opening of the mitochondrial permeability transition pore (mPTP). This was 
examined in tetramethylrhodamin (TMRM)-loaded cardiomyocytes with either hypoxanthine 
(HX) or uric acid (UA) in indicated concentrations added to the buffer. Results are % of mean 
value in corresponding control groups (97.8±10.5 and 108.5±22.6 sec). Mean ± SEM, n=5-7. 
(F=4.24, p<0.008), *p<0.05 vs. control. B) Uric acid lowered mitochondrial oxidative 
phosphorylation at sub-maximal and maximal ADP concentrations (ADP and ADP max, 
respectively) and lowered the respiratory control ratio (RCR). Oxygen flux was normalized to 





 Although uric acid (UA) is associated with pathological detriment in heart 
disease, it also functions as an antioxidant in human plasma, and is a potent scavenger of 
peroxynitrite in the extracellular compartment (Juhasz et al. 2011; Kuzkaya et al. 2005). 
The present study confirms that presence of UA, at human concentrations, modulates the 
response to ischemia. UA 1) reduces ex-vivo ischemia-reperfusion injury when combined 
with increased perfusion pressure, 2) blocks cardioprotection by ischemic 
preconditioning (IPC), and 3) protects against mitochondrial pore opening in isolated 
myocardial cells. Thus, this study confirms that concentrations corresponding to those 
normally present in human blood could have an infarct-sparing effect. 
Cardioprotection by IPC is dependent on signaling ROS, where one cycle of five 
minutes of ischemia followed by five minutes of reperfusion triggers an adaptation 
(Sovershaev et al. 2006; Starkopf et al. 1998). Here, peroxynitrite is considered to play a 
central role (Laude et al. 2002). However, limitation of reperfusion injury by different 
cardio-protective treatments such as UA or XO inhibition, is also closely associated with 
reduction in ROS (George et al. 2006; Pagliaro and Penna 2015). Thus, our results are in 
agreement with the proposed scavenging effects of acute elevations of UA seen in 
previous studies (Babiker et al. 2017; Lee et al. 2003; Mozaffari et al. 2011).Pressure 
overload (increased perfusion pressure) at reperfusion after prolonged ischemia increases 
reperfusion injury in experimental studies (Gunnes et al. 1990; Mozaffari et al. 2011; 
Mozaffari and Schaffer 2008). The present findings partly confirms earlier studies 
demonstrating that abrupt restoration of perfusion pressure after global ischemia might 
add to injury if pressure is elevated, and supports the notion that blood pressure control is 
important during reperfusion therapy (Lindal et al. 1990; Pedrinelli et al. 2012; 
Reinstadler et al. 2016). Interestingly, we did not find UA or allopurinol to reduce the 
elevated developed pressure in HP-perfused hearts. In contrast, the present study 
demonstrates that perfusion with allopurinol in pressure overloaded hearts resulted in an 
increased dP/dt max both at baseline and at the end of the ischemia-reperfusion protocol, 
which was not observed with UA. The reason for this was not examined in detail, but 
could be related to differences in pressure overload induced-ROS levels between these 
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studies, and the dose dependency of contractile performance during ROS exposure of 
isolated rat hearts (Hegstad et al. 1997; Xie et al. 1998).   
Consistent with previous reports that the activity of XO and ROS are central 
mechanisms contributing to aggravated ischemia-reperfusion induced cell death due to 
elevated perfusion pressure (Mozaffari et al. 2011), both UA and allopurinol reduced 
infarct size in isolated rat hearts in the present study. There are several sources of ROS in 
the heart, most of them proposed to be active in relation to ischemia-reperfusion injury 
and vascular dysfunction (Granger and Kvietys 2015). The combination of high oxygen 
demand/oxidative stress, and NO stimulation in the vessels by pressure overload, can 
promote peroxynitrite formation, and trigger XO activity (Mozaffari et al. 2011). HP-
perfusion induced increase in oxygen demand may also contribute to a lower cardiac 
efficiency, which has previously been related to increased susceptibility to ischemia-
reperfusion injury (Lund et al. 2015). However, reduced cardiac efficiency is unlikely to 
be the primary cause of HP-induced increase in cell death as allopurinol treatment also 
reduced cell death following IR, despite increased contractile work. HP-perfusion itself 
also significantly affected the degree of phosphorylation of various cell survival related 
signaling kinases, Akt, ERK and GSK3β, which are linked to cardioprotection by 
preconditioning (Hausenloy et al. 2017; Johansen et al. 2011; Juhaszova et al. 2004). In 
contrast to these studies, increased phosphorylation of AKT, ERK and GSK3β was 
associated with markedly increased infarct size. Moreover, IPC-induced cardioprotection 
was observed in HP-perfused hearts. UA and allopurinol did not affect phosphorylation 
of these kinases prior to ischemia.  
 Under physiological conditions as well as in our perfusion solutions, UA exists as 
organic anion urate. Probenecid is a highly lipid soluble benzoic acid derivative used to 
inhibit urate reuptake in renal tubular cells. Interestingly, probenecid has been described 
as both a pannexin channel inhibitor as well as a urate re-uptake inhibitor (George et al. 
2006; Silverman et al. 2008). In the present study, probenecid prevented UA from 
blocking IPC-induced cardioprotection and supports that effective UA uptake does occur 
in the heart. Probenecid by itself did not modify infarct size or inhibit ischemic 
preconditioning. However, more studies are required to fully understand UA uptake 
mechanisms in cardiac cells.  
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The mitochondrial response to UA was also tested. UA delayed opening of the 
mPTP following acute exposure of isolated cardiomyocytes to intracellular ROS. This 
observation is most likely due to the ROS scavenger effect of UA and is in accordance 
with the ability of UA to reduce reperfusion injury and ischemic preconditioning under 
the conditions described in the present study. Few studies have looked at the direct 
effect of UA on mitochondrial function. There is a sustained interest in regulation of 
the mitochondrial membrane potential, which in turn, drives the F1F0-ATPase activity: 
However, how this is coupled to ATP degradation products like UA is not well 
clarified (Kristal et al. 1999). When cardiac mitochondria were incubated with UA, 
oxidative phosphorylation decreased slightly, but significantly. Purine metabolism 
differs between organs and cells and relates to ATP consumption, turnover of mtDNA 
and nuclear DNA as well as cellular enzymatic makeup, resulting in variable 
intracellular levels of UA. Differences in uptake from the extracellular space further 
adds to this complexity. Recently, Wang et al. proposed a strong coupling of ATP 
production and consumption via the mito-flash phenomenon and F1F0-ATPase (Gong 
et al. 2015; Wang et al. 2017).   
Limitations. Cells and tissue from rodents are not adapted to extracellular UA 
levels used in the present study, which are comparable to levels in human extracellular 
fluid. On one hand, the present study indicates that adding UA in amounts present in 
humans reveals an antioxidant effect of UA that is difficult to demonstrate in clinical 
studies. On the other hand, the study does not explain the significant association between 
plasma UA level and cardiovascular pathophysiology. The question of whether UA is a 
casual, compensatory, or coincidental factor in cardiovascular medicine remains 
unanswered, and needs to be solved on a human background (Carluccio et al. 2018; So 
and Thorens 2010) as well as in uricase-deficient experimental animals. So far, the 
number of studies with human derived cells and tissue comparing exposure to different 
UA concentrations are limited. Interestingly, a human study of individuals with loss of 
function mutations in UA transporter URAT1, which led to hypouricemia, described 
concomitant significant endothelial dysfunction (Sugihara et al. 2015).  
In conclusion, we have demonstrated that under experimental conditions in 
isolated perfused hearts, cardiomyocytes and mitochondria, the presence or absence of 
17 
 
UA in concentrations equivalent with human plasma concentrations, modulated the 
response to cardiac ischemia. UA behaved like a highly ambiguous agent, protecting 
against I/R injury under certain conditions and maintaining mitochondrial integrity, but 
also blocked protection by endogenous ischemic preconditioning of the heart and tended 
to reduce mitochondrial respiration. As UA is continuously present in human plasma, it 
may reduce the effect of conditioning treatments to enhance cardioprotection in human 
studies. Potential interference with UA should be tested when translating experimentally 
promising cardioprotective interventions towards clinical application, such as ischemic-
preconditioning.  
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